There is no sign of a slowdown in Johnston County's rapid growth, meaning things like cost of living and infrastructure are ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

Deals of the Year & Impact Awards entries spanned industries and investment levels. Here are the stories of this year’s picks ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

I’m cautious about Novo Nordisk's stock in the short term due to the recent selloff momentum, which could bottom out if the FDA rejects its petition to restrict compounding alternatives.

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE:NVO) following recent industry developments and competitive insights. The firm said in a note ...

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...